<- Go Home
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Market Cap
$995.2M
Volume
N/A
Cash and Equivalents
$26.8M
EBITDA
-$71.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$13.0M
Profit Margin
100.00%
52 Week High
$33.20
52 Week Low
$13.88
Dividend
N/A
Price / Book Value
-0.27
Price / Earnings
-0.77
Price / Tangible Book Value
-0.27
Enterprise Value
$1.2B
Enterprise Value / EBITDA
-16.99
Operating Income
-$72.8M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$76.1M
Debt
$765.0K
Equity
$73.9M
Revenue
$13.0M
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium